Literature DB >> 55450

Immunochemical characterization of the "native" type III polysaccharide of group B Streptococcus.

C J Baker, D L Kasper, C E Davis.   

Abstract

The type III polysaccharide of -roup B Streptococcus has been isolated and purified by a method that employs washing of intact cells at neutral pH. That the polysaccharide prepared by this procedure is the "native" type III antigen is suggested by its molecular size in excess of 10(6) daltons, its degradation by acid and heat treatment to a fragment with immunologic characteristics of the classical HCl antigen, and its type-specific serologic activity. The type III polysaccharide in native form contains sialic acid, galactose, glucose, glucosamine, heptose, and mannose. It is acidic in nature, is resistant to neuramindiase degradation, contains no O-acetyl groups, and does not share antigenic determinants with capsular type K1 antigen of Escherichia coli or Group B polysaccharide antigen of Neiserria meningitidis.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 55450      PMCID: PMC2190119          DOI: 10.1084/jem.143.2.258

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  27 in total

1.  Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis.

Authors:  J B Robbins; G H McCracken; E C Gotschlich; F Orskov; I Orskov; L A Hanson
Journal:  N Engl J Med       Date:  1974-05-30       Impact factor: 91.245

2.  The sialic acids. VI. Purification and properties of sialidase from Clostridium perfringens.

Authors:  J T Cassidy; G W Jourdian; S Roseman
Journal:  J Biol Chem       Date:  1965-09       Impact factor: 5.157

3.  Immunochemistry of purified polysaccharide type antigens of group B streptococcal types Ia, Ib, and Ic.

Authors:  H W Wilkinson
Journal:  Infect Immun       Date:  1975-04       Impact factor: 3.441

4.  Variation in the group-specific carbohydrate of group A streptococci. I. Immunochemical studies on the carbohydrates of variant strains.

Authors:  M McCARTY; R C LANCEFIELD
Journal:  J Exp Med       Date:  1955-07-01       Impact factor: 14.307

5.  Role of meningococcal endotoxin in meningococcal purpura.

Authors:  C E Davis; K Arnold
Journal:  J Exp Med       Date:  1974-07-01       Impact factor: 14.307

6.  Improvements in epoxy resin embedding methods.

Authors:  J H LUFT
Journal:  J Biophys Biochem Cytol       Date:  1961-02

7.  TWO SEROLOGICAL TYPES OF GROUP B HEMOLYTIC STREPTOCOCCI WITH RELATED, BUT NOT IDENTICAL, TYPE-SPECIFIC SUBSTANCES.

Authors:  R C Lancefield
Journal:  J Exp Med       Date:  1938-01-01       Impact factor: 14.307

8.  A SEROLOGICAL DIFFERENTIATION OF SPECIFIC TYPES OF BOVINE HEMOLYTIC STREPTOCOCCI (GROUP B).

Authors:  R C Lancefield
Journal:  J Exp Med       Date:  1934-03-31       Impact factor: 14.307

9.  A SEROLOGICAL DIFFERENTIATION OF HUMAN AND OTHER GROUPS OF HEMOLYTIC STREPTOCOCCI.

Authors:  R C Lancefield
Journal:  J Exp Med       Date:  1933-03-31       Impact factor: 14.307

10.  Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis.

Authors:  I W Devoe; J E Gilchrist
Journal:  J Exp Med       Date:  1973-11-01       Impact factor: 14.307

View more
  40 in total

Review 1.  Interaction of neonatal phagocytes with group B streptococcus: recognition and response.

Authors:  Philipp Henneke; Reinhard Berner
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

2.  A soluble suppressor T cell factor protects against experimental intraabdominal abscesses.

Authors:  D F Zaleznik; R W Finberg; M E Shapiro; A B Onderdonk; D L Kasper
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

3.  Surface protein of a Streptococcus agalactiae isolate.

Authors:  B J de Cueninck
Journal:  Infect Immun       Date:  1979-06       Impact factor: 3.441

4.  Morphological stabilization of capsules of group B streptococci, types Ia, Ib, II, and III, with specific antibody.

Authors:  E B Mackie; K N Brown; J Lam; J W Costerton
Journal:  J Bacteriol       Date:  1979-05       Impact factor: 3.490

5.  Possible virulence marker for Streptococcus agalactiae (Lancefield Group B).

Authors:  G Orefici; S Recchia; L Galante
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-04       Impact factor: 3.267

6.  Association of type- and group-specific antigens with the cell wall of serotype III group B streptococcus.

Authors:  T I Doran; S J Mattingly
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

7.  Guanidine extraction enhances the binding of human fibrinogen to group-B streptococci.

Authors:  G S Chhatwal; C Lämmler; H Blobel
Journal:  Med Microbiol Immunol       Date:  1984       Impact factor: 3.402

8.  Type-specific capsular antigen is associated with virulence in late-onset group B Streptococcal type III disease.

Authors:  M E Klegerman; K M Boyer; C K Papierniak; L Levine; S P Gotoff
Journal:  Infect Immun       Date:  1984-04       Impact factor: 3.441

9.  Class specificity of naturally acquired and vaccine-induced antibody to type III group B streptococcal capsular polysaccharide: determination with a radioimmunoprecipitin assay.

Authors:  M S Edwards; P A Fuselier; M A Rench; D L Kasper; C J Baker
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

10.  Detection of group B streptococcal antibodies in human sera by radioimmunoassay: concentrations of type-specific antibodies in sera of adults and infants infected with group B streptococci.

Authors:  H W Wilkinson
Journal:  J Clin Microbiol       Date:  1978-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.